Dr. Damien Kenny:

I thank the Senator for the questions. On the validation testing, the system has been validated against four lab-based systems and has shown a specificity and sensitivity of approximately 99% across those testing strategies. The system is being used in the US at the moment, and is being used for testing. I think there have been well over 1 million tests performed to date in the US with this technology. This is without the need for backup laboratory testing because it has been accepted that it is an accurate, adequate stand-alone test for patients for assessing whether or not they have any presence of RNA virus in the context of SARS-CoV-2. On the costs and commercial aspects, I might hand over to my colleague, Mr. Lord, because he probably has better grasp of it.